Chris M Pillar Selected Research

dalbavancin

2/2017

Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chris M Pillar Research Topics

Disease

4	Infections 02/2017 - 09/2004
2	Invasive Candidiasis 03/2024 - 11/2017
2	Candidemia 03/2024 - 11/2017
2	Eye Infections 10/2011 - 08/2009
1	Invasive Fungal Infections 12/2019
1	Candidiasis (Moniliasis) 11/2017
1	Urinary Tract Infections (Urinary Tract Infection) 04/2015
1	Bacterial Infections (Bacterial Infection) 01/2013
1	Bacterial Conjunctivitis 07/2010
1	Intraabdominal Infections 12/2008
1	Cross Infection (Nosocomial Infection) 03/2008

Drug/Important Bio-Agent (IBA)

5	Anti-Bacterial Agents (Antibiotics)IBA 04/2015 - 09/2004
3	FluoroquinolonesIBA 10/2011 - 08/2009
2	EchinocandinsIBA 03/2024 - 11/2017
2	RezafunginIBA 03/2024 - 11/2017
2	tedizolidIBA 02/2017 - 09/2012
2	besifloxacin FDA Link 07/2010 - 08/2009
1	Caspofungin (Cancidas)FDA Link 03/2024
1	ProdrugsIBA 12/2019
1	AzolesIBA 11/2017
1	telavancin FDA Link 02/2017
1	dalbavancinIBA 02/2017
1	oritavancinIBA 02/2017
1	LipoglycopeptidesIBA 02/2017
1	Ceftaroline FDA Link 02/2017
1	eravacyclineIBA 04/2015
1	tedizolid phosphateIBA 09/2012
1	AminoglycosidesIBA 10/2011
1	MacrolidesIBA 10/2011
1	LactamsIBA 10/2011
1	Chloramphenicol (Chloromycetin)FDA Link 10/2011
1	Cephalosporins (Cephalosporin Antibiotics)IBA 10/2011
1	GlycopeptidesIBA 10/2011
1	Carbapenems (Carbapenem Antibiotics)IBA 12/2008
1	Doripenem FDA Link 12/2008
1	1 beta-methylcarbapenemIBA 12/2008
1	ceftobiproleIBA 03/2008